Tuberculous peritonitis

Summary

Tuberculous peritonitis (MONDO:0006000) is a disease and 1 clinical trial. A subtype of abdominal tuberculosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tuberculous peritonitis
Mondo ID	MONDO:0006000
EFO	EFO:0007529
MeSH	D014395
DOID	DOID:9801
ICD-10-CM	A18.31
ICD-11	925657864
SNOMED CT	44572005
UMLS	C0041325
MedGen	22516
GARD	0024268
Is cancer (heuristic)	no

Also known as: Mycobacterium tuberculosis caused peritonitis · Mycobacterium tuberculosis peritonitis

Disease family

This is a subtype of abdominal tuberculosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › tuberculosis › extrapulmonary tuberculosis › abdominal tuberculosis › tuberculous peritonitis

Related subtypes (4): hepatic tuberculosis, renal tuberculosis, splenic tuberculosis, tuberculous ascites

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04232384	Not specified	TERMINATED	Comparison of Roll-over’ Technique With Standard Abdominal Paracentesis in Suspected Peritoneal Carcinomatosis